New pill combo aims to tame tough bone marrow cancer
NCT ID NCT07006025
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an oral combination of tetrahydrouridine and decitabine in 20 adults with myelodysplastic syndromes (MDS) that returned or didn't respond to prior therapy. The main goals are to check safety and see if the drug improves blood cell counts and reduces hospital stays. Participants take the pills once a week for 24 weeks and visit the clinic monthly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Einstein Medical Center
RECRUITINGThe Bronx, New York, 10467, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Frailty check may steer safer cancer care for seniors
- Can a different immune drug cut viral infections after stem cell transplants?
- Supercharged donor cells aim to stop leukemia return after transplant
- Worldwide data pool could pave the way for mitochondrial disease trials
- New drug cocktail aims to boost transplant success in tough leukemias
- New hope for tough blood cancers? early trial tests LYT-200